<DOC>
	<DOCNO>NCT00005832</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness R115777 treat patient locally advance metastatic pancreatic cancer .</brief_summary>
	<brief_title>S9924 R115777 Treating Patients With Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine six month survival rate patient advance adenocarcinoma pancreas treat R115777 . II . Determine time treatment failure confirm response patient population treat regimen . III . Evaluate frequency severity toxicity associate treatment regimen patient . OUTLINE : Patients receive oral R115777 twice daily day 1-21 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients follow every 6 month 2 year annually thereafter . PROJECTED ACCRUAL : A total 21-50 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma pancreas Ductal adenocarcinoma Mucinous noncystic carcinoma Signet ring cell carcinoma Adenosquamous carcinoma Undifferentiated ( anaplastic ) carcinoma Mixed ductal endocrine carcinoma Well differentiate adenocarcinoma Moderately well poorly differentiate adenocarcinoma Undifferentiated ductal carcinoma No papillary cystic carcinoma , sarcoma , tumor arise endocrine pancreas Pathological confirmation metastatic site allow Clinical documentation pancreatic involvement evidence another primary allow Locally advance distant metastatic disease surgically incurable No known brain metastasis PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 2.5 time ULN Renal : Creatinine great 2.0 mg/dL Other : Ability swallow and/or receive enteral medication via gastrostomy feed tube No intractable nausea vomit No prior malignancy within past 5 year except adequately treat basal squamous cell skin cancer , carcinoma situ cervix , stage I II cancer remission Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior concurrent immunotherapy Chemotherapy : No prior chemotherapy No prior adjuvant neoadjuvant chemoradiotherapy , include advanced pancreatic cancer No concurrent chemotherapy Endocrine therapy : No prior concurrent hormonal therapy Radiotherapy : See Chemotherapy No prior radiotherapy , except palliation metastatic sit No concurrent radiotherapy Surgery : See Disease Characteristics At least 2 week since prior surgery pancreatic cancer recover Prior partial resection stomach duodenum pancreatic cancer allow No prior major resection small intestine Prior pancreaticduodenectomy pancreatic cancer allow Other : No concurrent proton pump inhibitor ( e.g. , omeprazole ) Concurrent antacid H2 blocker allow No concurrent therapy pancreatic cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>duct cell adenocarcinoma pancreas</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>